Lenvatinib treatment decreased the number of CD31+ tumor blood vessels, diminished the amount of CD11b+F4/80+ TAMs and increased the percentage of activated CD8+ T cells secreting interferon (IFN)-γ+ and granzyme B (GzmB) in CT26 colon cancer mouse model. This evidence concerns the gene CD8A and colonic neoplasm.